ENvue Medical develops medical technology for enteral care, with a commercial focus on real-time guided bedside feeding tube placement. Its ENvue Navigation Platform is an FDA 510(k)-cleared electromagnetic navigation system for adult use that provides visual guidance as clinicians place feeding tubes into the gastrointestinal tract.
Company news commonly covers hospital adoption, group purchasing and distribution agreements, commercialization updates, and product-line expansion for ENFit syringes and enteral supplies. Updates also include intellectual-property activity tied to feeding tube navigation and the company's surface acoustic wave platform, including acoustic therapeutic technologies such as PainShield and UroShield for pain, bacterial colonization, and biofilm-related applications.
ENvue Medical (FEED) has begun U.S. production of UroShield and commercial shipments to its exclusive distributor, Peak Medical.
Peak Medical covers the United Kingdom and Republic of Ireland. ENvue is fulfilling existing orders under a multi-year agreement with multi-million-dollar minimum purchase commitments through December 2029. The start follows commercial PainShield shipments to Ultra Pain Products, its exclusive U.S. distribution partner, in September 2026. Both products are now shipping commercially as ENvue transitions its therapeutic ultrasound manufacturing operations to the United States.
ENvue Medical (FEED) issued a shareholder letter outlining plans to expand commercial activity and pursue profitability with a leaner organization. Following its stock's transition from Nasdaq to the OTC market, the company is evaluating ways to strengthen capital and improve share liquidity.
NanoVibronix transferred manufacturing from Israel to the United States in August 2026; shipments of U.S.-manufactured PainShield resumed to Ultra Pain Products in September. Its exclusive UroShield agreement with Peak Medical includes approximately $2.6 million in minimum purchase commitments through December 2029.
ENvue plans to expand hospital access and recurring feeding tube sales while controlling costs. It demonstrated an ENvue Drive prototype in July 2026, but has not submitted it for FDA clearance or approval. Further work depends on financial resources and commercial priorities and requires additional development, testing and regulatory work before commercialization.
ENvue Medical (FEED) received a Nasdaq Hearings Panel decision on September 15, 2026 denying its request for continued listing on The Nasdaq Capital Market.
Trading of the company’s common stock will be suspended from Nasdaq and is expected to begin on the OTC Markets under the same ticker, FEED, on September 16, 2026. ENvue states that the decision does not affect its business operations, products, customers, or ongoing commercial activities. The company remains focused on commercialization of its ENvue Navigation System and other technologies, and is evaluating all available procedures and alternatives under Nasdaq Listing Rules, including a further appeal.
ENvue Medical (FEED) has resumed U.S. commercial shipments of NanoVibronix PainShield and begun fulfilling open orders from Ultra Pain Products, its exclusive U.S. distribution partner. This follows completion of ENvue’s transition of NanoVibronix manufacturing from Israel to the United States. With U.S. production now operational, ENvue is restoring commercial supply, supporting distributors and aiming to rebuild growth in the NanoVibronix business.
ENvue Medical (FEED) will exhibit its ENvue™ Navigation Platform at the Vizient® Innovative Technology Exchange on September 24, 2026, in Las Vegas, Nevada. The platform is a minimally invasive electromagnetic navigation system designed for real-time guided bedside feeding tube placement.
The Exchange allows selected suppliers to demonstrate technologies to supply chain and clinical leaders from Vizient’s hospital clients. ENvue highlights that its system enables real-time confirmation of feeding tube placement without X-ray, and cites an independent study of 531 procedures reporting zero inadvertent lung placements, a 67% reduction in ventilator-associated pneumonia, and an estimated first-year hospital cost avoidance of over $1.5 million based on AHRQ benchmarks.
ENvue Medical (NASDAQ: FEED) has approved a 1-for-12 reverse stock split of its issued and outstanding common stock, expected to become effective on September 1, 2026. FEED will continue trading on the Nasdaq Capital Market under the same ticker, but with new CUSIP 63008J876.
According to ENvue Medical, every twelve pre-split shares will be combined into one post-split share, reducing outstanding common shares from 11,084,616 to approximately 923,718, while authorized common shares remain at 40,000,000. Fractional shares will be rounded up to the nearest whole share per stockholder, and equity awards and convertible securities will be proportionally adjusted.
ENvue Medical (NASDAQ: FEED) entered a multi-year exclusive distribution agreement with Peak Medical to commercialize its UroShield® device across the United Kingdom and Republic of Ireland.
The agreement runs through December 31, 2029 and includes increasing annual minimum purchase commitments, from 650 units in 2026 to 35,000 units in 2029. In aggregate, Peak Medical’s minimum purchase commitments total approximately £2.1 million (about $2.6 million) over the initial term. ENvue said the deal is intended to expand market access and support revenue growth for UroShield, part of its NanoVibronix acoustic-based therapeutic product line.
ENvue Medical (NASDAQ: FEED) entered a securities purchase agreement with an institutional investor for an equity line of credit (“ELOC”) providing up to $50 million in capital, forming an equity financing facility (the “Facility). The Facility is subject to specified terms, including receipt of stockholder approval.
According to ENvue, the Facility is intended to enhance financial flexibility, fund advancement of its next-generation medical technology platform, and support evaluation of selective strategic acquisitions and business development opportunities. The company’s near-term priorities include accelerating adoption of its ENvue feeding tube navigation system, expanding its installed hospital base, increasing recurring feeding tube revenue, advancing navigation, AI and automation technologies, improving operating efficiency and disciplined capital allocation, and evaluating accretive acquisitions that could broaden its product portfolio and market reach.
ENvue Medical (NASDAQ: FEED) has completed moving manufacturing of its NanoVibronix product line from Israel to the United States and consolidated its research and development operations in Tel Aviv, Israel. The company states these changes support its broader plan to reduce operating expenses and improve its cost structure.
According to ENvue Medical, domestic manufacturing is expected to enhance operational efficiency, reduce costs, streamline supply chain management, and improve operational oversight. The NanoVibronix line, including PainShield and UroShield, uses proprietary low-intensity surface acoustic wave technology for home or care settings.
ENvue Medical (NASDAQ: FEED) announced the deployment of an additional ENvue™ Navigation Platform at an existing major academic medical center in the Dallas-Fort Worth Metroplex. The hospital, which treats a high volume of hospitalized patients, is expanding use of the system as clinician adoption grows across care settings.
The ENvue platform delivers real-time bedside visualization for feeding tube placement using a minimally invasive electromagnetic navigation system that is FDA 510(k) cleared for adult use. According to ENvue Medical, strengthening its presence in the Dallas-Fort Worth healthcare market is an important element of its commercial strategy.